featured
New Data on Immunotherapy for Small-Cell Lung Cancer
Interview by
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Antonia SJ, Lopez-Martin JA, Bendell JC, et al. Patrick Alexander Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 100.
- Ott PA, Elez Fernandez ME, Hiret S, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. Paper presented at: 2015 Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2015; Chicago, IL. Abstract 7502.
- Rudin CM, Pietanza MC, Bauer TM, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract LBA8505.